Table 1.
Population characteristics (N = 125)
| Characteristics | No | Percentage (%) |
|---|---|---|
| HER2 status | ||
| Positive | 0 | 0.0 |
| Negative | 125 | 100.0 |
| Hormone receptor status | ||
| Positive | 110 | 88.0 |
| Negative | 15 | 12.0 |
| Age at diagnosis | ||
| ≤35 | 20 | 16.0 |
| 35–60 | 96 | 76.8 |
| >60 | 9 | 7.2 |
| Tumor stage at initial diagnosis | ||
| I | 17 | 13.6 |
| II | 41 | 32.8 |
| III | 32 | 25.6 |
| IV | 14 | 11.2 |
| Unknown | 21 | 16.8 |
| Nuclear grade | ||
| 1 | 2 | 1.6 |
| 2 | 56 | 44.8 |
| 3 | 20 | 16.0 |
| Unknown | 47 | 37.6 |
| Disease-free survival (months) | ||
| ≤12 | 24 | 19.2 |
| 12–24 | 17 | 13.6 |
| 24–60 | 43 | 34.4 |
| >60 | 40 | 32.0 |
| Unknown | 1 | 0.8 |
| Number of metastatic sites | ||
| 1 | 33 | 26.4 |
| 2–3 | 72 | 57.6 |
| ≥4 | 22 | 17.6 |
| Visceral metastases | ||
| Yes | 41 | 32.8 |
| No | 86 | 68.8 |
| Previous endocrine therapy (after confirmed tumor relapse) | ||
| Yes | 33 | 26.4 |
| No | 92 | 73.6 |